added PTLD data to Crins example

data/CrinsEtAl2014.R

@@ -24,10 +24,12 @@ CrinsEtAl2014 <- data.frame("publication"=c("Spada (2006)", "Ganschow (2005)",
                             "followup"=c(12,36,6,24,6,36),
                             "exp.AR.events"=c(4,9,16,14,3,0),
                             "exp.SRR.events"=c(NA,4,NA,2,NA,1),
+                            "exp.PTLD.events"=c(1,1,NA,NA,0,NA),
                             "exp.deaths"=c(4,1,NA,4,NA,2),
                             "exp.total"=c(36,54,28,61,18,50),
                             "cont.AR.events"=c(11,29,19,15,8,3),
                             "cont.SRR.events"=c(NA,6,NA,4,NA,4),
+                            "cont.PTLD.events"=c(1,0,NA,NA,0,NA),
                             "cont.deaths"=c(3,3,NA,3,NA,3),
                             "cont.total"=c(36,54,28,20,12,34),
                             stringsAsFactors=FALSE)[c(4,3,5,2,1,6),]

man/CrinsEtAl2014.Rd

@@ -3,34 +3,37 @@
 \alias{CrinsEtAl2014}
 \title{Pediatric liver transplant example data}
 \description{Numbers of cases (transplant patients) and events (acute rejections,
-  steroid resistant rejections, and deaths) in experimental and control groups of
+  steroid resistant rejections, PTLDs, and deaths) in experimental and control groups of
   six studies.}
 \usage{data("CrinsEtAl2014")}
 \format{The data frame contains the following columns:
   \tabular{lll}{
-    \bold{publication}        \tab \code{character} \tab publication identifier (first author and publication year) \cr
-    \bold{year}               \tab \code{numeric}   \tab publication year \cr
-    \bold{randomized}         \tab \code{factor}    \tab randomization status (y/n) \cr
-    \bold{control.type}       \tab \code{factor}    \tab type of control group (\sQuote{concurrent} or \sQuote{historical})\cr
-    \bold{comparison}         \tab \code{factor}    \tab type of comparison (\sQuote{IL-2RA only}, \sQuote{delayed CNI}, or \sQuote{no/low steroids}) \cr
-    \bold{IL2RA}              \tab \code{factor}    \tab type of interleukin-2 receptor antagonist (IL-2RA) (\sQuote{basiliximab} or \sQuote{daclizumab}) \cr
-    \bold{CNI}                \tab \code{factor}    \tab type of calcineurin inhibitor (CNI) (\sQuote{tracrolimus} or \sQuote{cyclosporine A}) \cr
-    \bold{MMF}                \tab \code{factor}    \tab use of mycofenolate mofetil (MMF) (y/n) \cr
-    \bold{followup}           \tab \code{numeric}   \tab follow-up time in months \cr
-    \bold{treat.AR.events}    \tab \code{numeric}   \tab number of AR events in experimental group \cr
-    \bold{treat.SRR.events}   \tab \code{numeric}   \tab number of SRR events in experimental group \cr
-    \bold{treat.deaths}       \tab \code{numeric}   \tab number of deaths in experimental group \cr
-    \bold{treat.total}        \tab \code{numeric}   \tab number of cases in experimental group \cr
-    \bold{control.AR.events}  \tab \code{numeric}   \tab number of AR events in control group \cr
-    \bold{control.SRR.events} \tab \code{numeric}   \tab number of SRR events in control group \cr
-    \bold{control.deaths}     \tab \code{numeric}   \tab number of deaths in control group \cr
-    \bold{control.total}      \tab \code{numeric}   \tab number of cases in control group \cr
+    \bold{publication}         \tab \code{character} \tab publication identifier (first author and publication year) \cr
+    \bold{year}                \tab \code{numeric}   \tab publication year \cr
+    \bold{randomized}          \tab \code{factor}    \tab randomization status (y/n) \cr
+    \bold{control.type}        \tab \code{factor}    \tab type of control group (\sQuote{concurrent} or \sQuote{historical})\cr
+    \bold{comparison}          \tab \code{factor}    \tab type of comparison (\sQuote{IL-2RA only}, \sQuote{delayed CNI}, or \sQuote{no/low steroids}) \cr
+    \bold{IL2RA}               \tab \code{factor}    \tab type of interleukin-2 receptor antagonist (IL-2RA) (\sQuote{basiliximab} or \sQuote{daclizumab}) \cr
+    \bold{CNI}                 \tab \code{factor}    \tab type of calcineurin inhibitor (CNI) (\sQuote{tracrolimus} or \sQuote{cyclosporine A}) \cr
+    \bold{MMF}                 \tab \code{factor}    \tab use of mycofenolate mofetil (MMF) (y/n) \cr
+    \bold{followup}            \tab \code{numeric}   \tab follow-up time in months \cr
+    \bold{treat.AR.events}     \tab \code{numeric}   \tab number of AR events in experimental group \cr
+    \bold{treat.SRR.events}    \tab \code{numeric}   \tab number of SRR events in experimental group \cr
+    \bold{treat.PTLD.events}   \tab \code{numeric}   \tab number of PTLD events in control group \cr
+    \bold{treat.deaths}        \tab \code{numeric}   \tab number of deaths in experimental group \cr
+    \bold{treat.total}         \tab \code{numeric}   \tab number of cases in experimental group \cr
+    \bold{control.AR.events}   \tab \code{numeric}   \tab number of AR events in control group \cr
+    \bold{control.SRR.events}  \tab \code{numeric}   \tab number of SRR events in control group \cr
+    \bold{control.PTLD.events} \tab \code{numeric}   \tab number of PTLD events in control group \cr
+    \bold{control.deaths}      \tab \code{numeric}   \tab number of deaths in control group \cr
+    \bold{control.total}       \tab \code{numeric}   \tab number of cases in control group \cr
   }
 }
 \details{A systematic literature review investigated the evidence on the
   effect of Interleukin-2 receptor antagonists (IL-2RA) and resulted in
-  six controlled studies reporting acute rejection (AR) and
-  steroid-resistant rejection (SRR) rates as well as mortality in
+  six controlled studies reporting acute rejection (AR),
+  steroid-resistant rejection (SRR) and post-transplant
+  lymphoproliferative disorder (PTLD) rates as well as mortality in
   pediatric liver transplant recipients.
 }
 \source{N.D. Crins, C. Roever, A.D. Goralczyk, T. Friede.